2018-02-16 15:05:35 UTC

FDA Announces GREAT 5 Public Workshop

Feb. 16, 2018

The three-day public workshop will focus on alcoholic hepatitis and liver disease, and pediatric IBS and functional constipation.

The FDA is cosponsoring a public workshop with AGA, AASLD, ACG, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) — the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT 5).

The public workshop aims to facilitate ongoing dialogue among relevant parties on issues related to alcoholic hepatitis and alcohol associated liver disease (March 26-27) and pediatric irritable bowel syndrome (IBS) and pediatric functional constipation (March 28) from 8 a.m. – 5 p.m.  

At this time, live streaming of the presentations is planned and transcripts of the presentations will be available within 30 days following the workshop. Live streaming may be accessed at https://collaboration.fda.gov/greatv/.  

On-site registration will not be available. Participants (both in-person attendees and remote participants) need to register in advance to attend.

Email questions related to registration.

Review information on the venue, local hotels and FDA campus security procedures.

More on Constipation

Choose from 30 breakout sessions at the 2018 AGA Postgraduate Course

March 22, 2018

Delve deeper into specific clinical topics that interest you and get concrete action items that can be immediately implemented into your practice.

2018 AGA Postgraduate Course explores disorders of the colon and rectum

March 7, 2018

Sessions will explore recent advances to help take your practice to the next level.

Share feedback on AGA constipation guideline

March 5, 2018

AGA's new guideline on medical management of opioid-induced constipation is open until March 30.